212 related articles for article (PubMed ID: 33298139)
1. Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.
Sereesongsaeng N; McDowell SH; Burrows JF; Scott CJ; Burden RE
Breast Cancer Res; 2020 Dec; 22(1):139. PubMed ID: 33298139
[TBL] [Abstract][Full Text] [Related]
2. LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis.
Liu SQ; Zhou ZY; Dong X; Guo L; Zhang KJ
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32538432
[TBL] [Abstract][Full Text] [Related]
3. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
4. The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
Yildirim E; Bektas S; Gundogar O; Findik D; Alcicek S; Erdogan KO; Yildiz M
Anticancer Res; 2020 Oct; 40(10):5649-5657. PubMed ID: 32988889
[TBL] [Abstract][Full Text] [Related]
5. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
6. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition.
Yan W; Cao QJ; Arenas RB; Bentley B; Shao R
J Biol Chem; 2010 Apr; 285(18):14042-51. PubMed ID: 20189993
[TBL] [Abstract][Full Text] [Related]
7. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
8. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
9. The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer.
Fararjeh AS; Tu SH; Chen LC; Liu YR; Lin YK; Chang HL; Chang HW; Wu CH; Hwang-Verslues WW; Ho YS
Hum Pathol; 2018 Oct; 80():219-230. PubMed ID: 29902578
[TBL] [Abstract][Full Text] [Related]
10. SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.
Hassan N; Rutsch N; Győrffy B; Espinoza-Sánchez NA; Götte M
Sci Rep; 2020 Feb; 10(1):2262. PubMed ID: 32042016
[TBL] [Abstract][Full Text] [Related]
11. Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells.
Emmanuel N; Lofgren KA; Peterson EA; Meier DR; Jung EH; Kenny PA
Anticancer Res; 2018 Aug; 38(8):4435-4441. PubMed ID: 30061207
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
[TBL] [Abstract][Full Text] [Related]
13. GATA3 mutations found in breast cancers may be associated with aberrant nuclear localization, reduced transactivation and cell invasiveness.
Gaynor KU; Grigorieva IV; Allen MD; Esapa CT; Head RA; Gopinath P; Christie PT; Nesbit MA; Jones JL; Thakker RV
Horm Cancer; 2013 Jun; 4(3):123-39. PubMed ID: 23435732
[TBL] [Abstract][Full Text] [Related]
14. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.
Chou J; Lin JH; Brenot A; Kim JW; Provot S; Werb Z
Nat Cell Biol; 2013 Feb; 15(2):201-13. PubMed ID: 23354167
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
16. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.
Cohen H; Ben-Hamo R; Gidoni M; Yitzhaki I; Kozol R; Zilberberg A; Efroni S
Breast Cancer Res; 2014 Nov; 16(6):464. PubMed ID: 25410484
[TBL] [Abstract][Full Text] [Related]
17. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
[TBL] [Abstract][Full Text] [Related]
18. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
19. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
